Start patients at increased risk for hypoglycemia (e.g. The dosage and the half-life of the previous antidiabetic agent should be taken into account when switching to Gliclazide 80 mg Tablets. Since gliclazide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered.Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur when one of the following drugs is taken, for example: Other antidiabetic agents (insulins, acarbose, biguanides (e.g. It potentiates the insulin release,improves the dynamics of insulin. • Withdrawal of prolonged and/or high dose corticosteroid therapy, Gliclazide is well absorbed. Adequate dose adjustment and dietary compliance should be considered before classifying the patient as secondary failure.Disturbances in blood glucose, including hypoglycaemia and hyperglycaemia have been reported, in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. A single dose should not exceed 160mg. This should be followed by continuous infusion of a more dilute glucose solution (10 %) at a rate that will maintain blood glucose levels above 1 g/L. Maximum dose: 8 mg per day Comments:-Administer with breakfast or first main meal of the day.-In patients who are at increased risk for hypoglycemia, start with 1 mg orally once a day and titrate slowly.-When patients are being transferred to this drug from a longer half-life sulfonylurea, monitor 1 to 2 weeks for overlapping drug effect. (see section 4.4)Based on the experience with gliclazide, the following undesirable effects have been reported.As for other sulfonylureas, treatment with Gliclazide 80 mg Tablets can cause hypoglycaemia, if mealtimes are irregular and, in particular, if meals are skipped. Precautions. Increase in postprandial insulin and C- peptide secretion persists after two years of treatment.In addition to these metabolic properties, gliclazide has haemovascular properties.In type 2 diabetics, gliclazide restores the first peak of insulin secretion in response to glucose and increases the second phase of insulin secretion. It allows continued monitoring of the benefit/risk balance of the medicinal product. A transitional period is not generally necessary. Discontinue treatment if cholestatic jaundice appears. A starting dose of 40-80 mg (½ to 1 tablet) should be used and this should be adjusted to suit the patient's blood glucose response, as described above. The dose should be adjusted according to the individual's response, commencing with 40-80mg daily and increasing until adequate control is achieved. Patients receiving immediate release glipizide may be switched to GLIPIZIDE XL once daily at the nearest equivalent total daily dose. Therefore, GLIPIZIDE XL should be administered at least 4 hours prior to colesevelam.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. This information is intended for use by health professionalsExcipient(s) with known effect: Lactose monohydrate White to off white, circular, flat faced beveled edge uncoated tablets with cross break line on one side and plain on other side.Non insulin dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.The total daily dose may vary from 40 to 320 mg taken orally. Fertility and reproductive performance were unaffected after gliclazide administration in animal studies.This medicinal product does not require any special storage conditions.The blisters and leaflet are inserted into cardboard cartons.1st Floor , Kirkland House, 1-15 Peterborough Road, HARROW, Middlesex, HA1 2AXTo bookmark a medicine you must sign up and log in.To view the changes to a medicine you must sign up and log in. • Severe renal or hepatic insufficiency: in these cases the use of insulin is recommended,This treatment should be prescribed only if the patient is likely to have a regular food intake (including breakfast). • an action on the vascular endothelium fibrinolytic activity with an increase in tPA activityPlasma levels increase reaching maximal concentrations between 2 and 6 hours. Adequate dose adjustment and dietary compliance should be considered before classifying the patient as secondary failure.Disturbances in blood glucose, including hypoglycaemia and hyperglycaemia have been reported, in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. Gliclazide decreases microthrombosis by two mechanisms which may be involved in complications of diabetes: If you miss a dose, take it as soon as remembered; do not take it if it is near the time for the next dose, instead, skip the missed dose and resume your usual dosing schedule. If hypoglycaemic coma is diagnosed or suspected, the patient should be given a rapid I.V. No active metabolites have been detected in plasma.The elimination half-life of gliclazide is between 10 and 12 hours.The relationship between the dose administered between 40 and 400mg and the mean plasma concentrations is linear.No clinically significant changes in pharmacokinetic parameters have been observed in elderly patients.Preclinical data reveal no special hazards for humans based on conventional studies of repeated dose toxicity and genotoxicity.